Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Refractory dermatomyositis responsive to anifrolumab
Phillip S. Ang, Ekene Ezenwa, K S Ko, et al.
JAAD Case Reports (2023) Vol. 43, pp. 27-29
Open Access | Times Cited: 15

Showing 15 citing articles:

Recalcitrant Dermatomyositis Treated With Anifrolumab
Shivang Chaudhary, Meghan Baumer, Laura Upton, et al.
ACR Open Rheumatology (2025) Vol. 7, Iss. 1
Open Access | Times Cited: 1
Immune-Mediated Necrotizing Myopathy (IMNM): A Story of Antibodies
Sarah Julien, Inès Challier, Marine Malleter, et al.
Antibodies (2024) Vol. 13, Iss. 1, pp. 12-12
Open Access | Times Cited: 4
Anifrolumab in Recalcitrant Cutaneous Dermatomyositis: A Multicenter Retrospective Cohort Study
Katharina S. Shaw, Kimberly B. Hashemi, Rochelle Castillo, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. 1217-1219
Closed Access | Times Cited: 4
The role of monocytes and macrophages in idiopathic inflammatory myopathies: insights into pathogenesis and potential targets
Shinji Izuka, Toshihiko Komai, Yumi Tsuchida, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Exploring Novel Therapies for Idiopathic Inflammatory Myopathies and Examining Future Perspectives
Luciana Molinero, Joan Padrosa, Iago Pinal‐Fernandez, et al.
Current Treatment Options in Rheumatology (2025) Vol. 11, Iss. 1
Closed Access
Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure
Alice Sohn, Nicole Bouché, George Michael Lewitt, et al.
JAAD Case Reports (2024) Vol. 51, pp. 97-99
Open Access | Times Cited: 1
Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases—A Narrative Review
Ichiro Kobayashi
Children (2024) Vol. 11, Iss. 9, pp. 1046-1046
Open Access | Times Cited: 1
[[Translated article]]Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses
Daniel Martín‐Torregrosa, Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Actas Dermo-Sifiliográficas (2024)
Open Access | Times Cited: 1
Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies
Hanna Kim
Pediatric Drugs (2024)
Open Access | Times Cited: 1
Anifrolumab for the Dermatologist
Cleo Whiting, Sara Abdel Azim, Adam Friedman
Journal of Drugs in Dermatology (2024) Vol. 23, Iss. 6, pp. 489-490
Open Access
“Uso del anifrolumab en el lupus eritematoso sistémico, lupus eritematoso cutáneo y otras dermatosis autoinmunes”
Daniel Martín‐Torregrosa, Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Actas Dermo-Sifiliográficas (2024)
Open Access
Comment on: Where are we now in biologic drugs for myositis?
Li-Heng Huang
Lara D. Veeken (2024) Vol. 63, Iss. 11, pp. e303-e304
Closed Access
A Novel Treatment for Skin Manifestations in Dermatomyositis: A Case Report
Manasa Srinivasa Murthy, Ammar Haikal
Cureus (2024)
Open Access
Successful Treatment of Refractory Cutaneous Manifestations of Dermatomyositis With Intravenous Immunoglobulin: A Case Report
Yousif B Aldoseri, Sahar Saad, Khalid B Aldoseri
Cureus (2024)
Open Access
Multiple drugs

Reactions Weekly (2024) Vol. 2028, Iss. 1, pp. 364-364
Closed Access
Page 1

Scroll to top